Associations - BRCA2 deletion

BIOMARKER:

BRCA2 deletion

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

BRCA2 deletion BRCA2 deletion	Prostate Cancer Prostate Cancer	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B
BRCA2 deletion BRCA2 deletion	Prostate Cancer Prostate Cancer	abiraterone acetate Sensitive: B - Late Trials abiraterone acetate Sensitive : B
BRCA2 deletion BRCA2 deletion	Prostate Cancer Prostate Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BRCA2 deletion BRCA2 deletion	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BRCA2 deletion BRCA2 deletion	Prostate Cancer Prostate Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
BRCA2 deletion BRCA2 deletion	Squamous Cell Skin Cancer Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
BRCA2 deletion BRCA2 deletion	Prostate Cancer Prostate Cancer	LY2606368 Sensitive: D – Preclinical LY2606368 Sensitive : D